Alkermes plc (NASDAQ: ALKS) today reported financial results for the third quarter of 2014.
“We enter the fourth quarter with strong momentum, and on the threshold of multiple data readouts for one of the most exciting and robust pipelines of new CNS medicines in the industry,” said Richard Pops, Chief Executive Officer of Alkermes. “Our most advanced candidate, aripiprazole lauroxil for the treatment of schizophrenia, builds on our experience in the increasingly important long-acting injectable antipsychotic class.
Help employers find you! Check out all the jobs and post your resume.
